Areteia Therapeutics Inc.

5 trials Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

3 Completed trials

12 Countries active

4 Unique IMPs

100% Results reported

Phase III

Oversight events:

1 urgent safety measure 1 corrective measure across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 5 BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE 2 SALBUTAMOL SULFATE 2 SALBUTAMOL SULFATE PH. EUR. 2

All trials

5 total

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Phase III 7 countries DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Not authorised

2023-503693-20-00 Phase III 1 country BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHY…
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Phase III 9 countries BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE; DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHY…
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Phase III 3 countries DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended

2023-509739-22-00 Phase III 2 countries DEXPRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

Showing 1–5 of 5 trials

← All sponsors A–Z